Azurrx Biopharma Inc., of Brooklyn, N.Y., said it reached an agreement in principle with Transchem Inc. to license its transition state chemistry technology for MTAN (methylthioadenosine/S-adenosylhomocysteine nucleosidase) inhibition, which plays a key role in bacterial quorum sensing.